Radiochemotherapy With Cisplatin and 5-Fluorouracil After Transurethral Surgery in Patients With Bladder Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 4, 2007, Pages 1072-1080

  Weiss, Christian ^a   Engehausen, Dirk G ^a   Krause, Frens S ^a   Papadopoulos, Thomas ^a   Dunst, Jürgen ^b   Sauer, Rolf ^a   Rödel, Claus ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

5 Fluorouracil; Bladder cancer; Cisplatin; Combined modality treatment; Radiochemotherapy

Indexed keywords

5-FLUOROURACIL; BLADDER CANCER; CISPLATIN; COMBINED MODALITY TREATMENT; RADIOCHEMOTHERAPY;

DRUG DELIVERY; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY; TUMORS;

CHEMOTHERAPY;

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYSTECTOMY; CYSTITIS; DIARRHEA; DISEASE SEVERITY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PATIENT SATISFACTION; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; URETHRA SURGERY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 34447272247     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.01.054     Document Type: Article

References (22)

1. Weiss C., Wolze C., Engehausen D.G., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy?. J Clin Oncol 24 (2006) 2318-2324
2. Rodel C., Weiss C., and Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24 (2006) 5536-5544
3. Coppin C.M., Gospodarowicz M.K., James K., et al., The National Cancer Institute of Canada Clinical Trials Group. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14 (1996) 2901-2907
4. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14 (1996) 119-126
5. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16 (1998) 3576-3583
6. Rodel C., Grabenbauer G.G., Kuhn R., et al. Organ preservation in patients with invasive bladder cancer: Initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys 52 (2002) 1303-1309
7. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 13-47
8. Rubin P., Constine L.S., Fajardo L.F., et al., RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 31 (1995) 1041-1042
9. Barry M.J., Fowler Jr. F.J., O'Leary M.P., et al., The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148 (1992) 1549-1557 discussion 1564
10. Housset M., Dufour B., Maulard-Durdux C., et al. A concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol (1997) 319a (Abstr.)
11. Zietman A.L., Shipley W.U., Kaufman D.S., et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 160 (1998) 1673-1677
12. Kaufman D.S., Winter K.A., Shipley W.U., et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5 (2000) 471-476
13. Chen W.C., Liaw C.C., Chuang C.K., et al. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 56 (2003) 726-733
14. Peyromaure M., Slama J., Beuzeboc P., et al. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: Report of a single institution. Urology 63 (2004) 73-77
15. Danesi D.T., Arcangeli G., Cruciani E., et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: Long term results. Cancer 101 (2004) 2540-2548
16. Kent E., Sandler H., Montie J., et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of a phase I trial. J Clin Oncol 22 (2004) 2540-2545
17. Sangar V.K., McBain C.A., Lyons J., et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 61 (2005) 420-425
18. Varveris H., Delakas D., Anezinis P., et al. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res 17 (1997) 4771-4780
19. Nichols Jr. R.C., Sweetser M.G., Mahmood S.K., et al. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: A well-tolerated combination. Int J Cancer 90 (2000) 281-286
20. Dunst J., Weigel C., Heynemann H., et al. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol 175 Suppl. 3 (1999) 7-10
21. Kaufman D., Winter K.A., Shipley W.U., et al. Muscle-invading bladder cancer, RTOG protocol 99-06: Initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy. [Abstract]. J Clin Oncol 23 (2005) 4506
22. Chakravarti A., Winter K., Wu C.L., et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62 (2005) 309-317